摘要
目的:评价3种喹诺酮类药物治疗上呼吸道感染的经济学效果。方法:采用回顾性研究方法,选择94例上呼吸道感染患者,随机分为A(左氧氟沙星)、B(乳酸环丙沙星)、C(莫西沙星)3组,观察疗效,并进行成本-效果分析。结果:A、B、C组的成本分别为397·60、1131·90、2255·40元,临床有效率分别为73·53%、85·71%、93·75%(P<0·05),成本-效果比分别为540·73、1320·62、2405·76。B、C组相对于A组的增量成本-效果比分别是6028·74、9187·93。结论:A组方案(左氧氟沙星)较经济。
OBJECTIVE： To evaluate the pharmacoeconomic effectiveness of three quinolones for respiratory tract infections. METHODS： A retrospective study was conducted in which a total of 94 cases with respiratory tract infection were randomly to receive levofloxacin （Group A）, ciprofloxacin （Group B） or moxifloxacin （Group C） . The therapeutic effects were monitored and the cost effectiveness analysis was performed on the three treatment schemes. RESULTS： The costs of the three groups were 397.60, 1 131.90, and 2 255.40 yuan, respectively; the clinical effective rates were 73.53%, 85.71% and 93.75%, respectively （P〈0.05） and the cost effectiveness ratios were 540.73, 1 320.62 and 2 405.76. And the incremental cost effectiveness ratios of Group B and Group C were 6 028.74 and 9 187.93 respectively as against Group A. CONCLUSION： Group A （levofloxacin） is the optimal one for respiratory tract infection.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第8期563-564,共2页
China Pharmacy
